Stockscreener 앱 받기
106.72
2.31%
2.41
시간 외 거래:
106.72
Revvity Inc 주식(RVTY)의 최신 뉴스
FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa
Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus
What's Going On With Revvity Stock Today? - Benzinga
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - 01net
Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener
FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing
Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha
Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - MarketScreener
FDA greenlights Revvity’s TB diagnostic platform - Investing.com India
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Zacks Investment Research
Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan
Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener
Is Revvity Stock Underperforming the Nasdaq? - MSN
High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Revvity Stock Underperforming The Nasdaq? - Barchart
Is Revvity Gaining or Losing Market Support? - Benzinga
Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks
Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN
The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace
Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener
Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan
May 16th Options Now Available For Revvity (RVTY) - Nasdaq
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity's AI-Powered Cellular Imaging & Research Antibodies - openPR
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Maintains Overweight Rating - MarketScreener
Learn to Evaluate (RVTY) using the Charts - Stock Traders Daily
Revvity at Leerink Global Healthcare Conference: Strategic Resilience Amid Challenges - Investing.com
Jones Financial Companies Lllp Acquires 1,228 Shares of Revvity, Inc. (NYSE:RVTY) - Defense World
Mutual of America Capital Management LLC Cuts Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
PerkinElmer Stock Price | RVTY Stock Quote, News, and History - Markets Insider
Sanctuary Advisors LLC Purchases Shares of 1,872 Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay - Technology Networks
Revvity, Inc. (NYSE:RVTY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Revvity Expands Measles Testing Accessibility with EUROIMMUN Anti-Measles Virus ELISA 2.0 - Lab Manager Magazine
Revvity's (NYSE:RVTY) Solid Earnings Have Been Accounted For Conservatively - Yahoo Finance
What Does the Market Think About Revvity? - Benzinga
Private Advisor Group LLC Grows Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity Says Euroimmun Gets CE Mark for Measles Antibody Detection -March 03, 2025 at 10:28 am EST - Marketscreener.com
High-Throughput Screening Technology Analysis and Global - GlobeNewswire
High-Throughput Screening Technology Analysis and Global Markets 2021-2024 & 2025-2029 with Danaher, Thermo Fisher Scientific., Charles River Laboratories, Revvity and Bio-Rad Laboratories Leading - Yahoo Finance
Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Jefferies raises Revvity stock price target to $130, maintains Hold - MSN
Is Revvity, Inc.'s (NYSE:RVTY) Stock Price Struggling As A Result Of Its Mixed Financials? - Simply Wall St
3 Reasons to Sell RVTY and 1 Stock to Buy Instead - Yahoo Finance
Principal Financial Group Inc. Sells 4,253 Shares of Revvity, Inc. (NYSE:RVTY) - Defense World
New York State Common Retirement Fund Reduces Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Do Options Traders Know Something About Revvity (RVTY) Stock We Don't? - MSN
Revvity Predicts Lower 2025 Earnings Despite Strong Fourth Quarter - Finimize
Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth Potential - Seeking Alpha
Revvity, Inc. (NYSE:RVTY) Shares Acquired by Vontobel Holding Ltd. - Defense World
Are Wall Street Analysts Bullish on Revvity Stock? - MSN
0.78%
1.81%
자본화:
|
볼륨(24시간):